- Home
- AUTL vs LRMR Comparison
AUTL vs LRMR Comparison
Compare AUTL & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUTL | LRMR |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 532.3M | 455.8M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AUTL | LRMR |
|---|---|---|
| Price | $2.43 | $4.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $8.50 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 3.3M | 1.1M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,120,000.00 | N/A |
| Revenue This Year | $80.32 | N/A |
| Revenue Next Year | $53.96 | $1,816.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 496.00 | N/A |
| 52 Week Low | $1.18 | $2.72 |
| 52 Week High | $2.58 | $6.42 |
Technical Indicators
Market Signals| Indicator | AUTL | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 64.81 | 53.29 |
| Support Level | $1.32 | $2.98 |
| Resistance Level | $2.43 | $4.21 |
| Average True Range (ATR) | 0.17 | 0.21 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 73.32 | 42.99 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.